Literature DB >> 22987944

New insights into ovarian cancer pathology.

J Prat1.   

Abstract

Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies. Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types [high-grade serous (70%), endometrioid (10%), clear-cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)] that account for over 95% of cases. These types are essentially distinct diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during oncogenesis, response to chemotherapy, and prognosis. For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical. The five tumor types are morphologically diverse and resemble carcinomas of the uterus. Actually, recent investigations have demonstrated that a substantial number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear-cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily. This presentation summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22987944     DOI: 10.1093/annonc/mds300

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  115 in total

Review 1.  Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma.

Authors:  Yiying Wang; Maggie Mang; Yue Wang; Lijie Wang; Robert Klein; Beihua Kong; Wenxin Zheng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 2.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

3.  Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator.

Authors:  Jun Sakata; Hiroaki Kajiyama; Shiro Suzuki; Fumi Utsumi; Kaoru Niimi; Ryuichiro Sekiya; Kiyosumi Shibata; Takeshi Senga; Fumitaka Kikkawa
Journal:  Oncol Lett       Date:  2017-07-24       Impact factor: 2.967

Review 4.  Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.

Authors:  Youngjoo Kwon; Andrew K Godwin
Journal:  Reprod Sci       Date:  2016-09-27       Impact factor: 3.060

Review 5.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08

6.  Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.

Authors:  Enrica Calura; Paolo Martini; Gabriele Sales; Luca Beltrame; Giovanna Chiorino; Maurizio D'Incalci; Sergio Marchini; Chiara Romualdi
Journal:  Nucleic Acids Res       Date:  2014-05-06       Impact factor: 16.971

Review 7.  The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.

Authors:  Kim Moran-Jones
Journal:  Mol Diagn Ther       Date:  2016-06       Impact factor: 4.074

Review 8.  Prediction of anti-angiogenesis escape.

Authors:  Takashi Mitamura; Charlie Gourley; Anil K Sood
Journal:  Gynecol Oncol       Date:  2015-12-31       Impact factor: 5.482

9.  Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

Authors:  Jinghong Jiang; Di Bo; Xiaohong Chang; Hongyan Cheng; Xue Ye; Heng Cui
Journal:  Int J Clin Exp Med       Date:  2015-11-15

10.  The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).

Authors:  Melissa Matz; Michel P Coleman; Milena Sant; Maria Dolores Chirlaque; Otto Visser; Martin Gore; Claudia Allemani
Journal:  Gynecol Oncol       Date:  2016-12-06       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.